培美曲塞联合顺铂治疗肺癌的临床观察

目的 探讨培美曲塞联合顺铂治疗肺癌的疗效、毒副作用.方法 选取100例肺癌患者,根据临床医生诊断和患者自身情况,分别选择长春瑞滨联合顺铂治疗(对照组)及培美曲塞联合顺铂治疗(实验组),每组各50例.随访治疗前后2组患者感染发生率、治疗效果、免疫情况和不良反应等常规参数,并对数据进行统计分析.结果 化疗改变了对照组和实验组患者体内T细胞亚群表达.治疗后实验组患者CD3、CD4细胞百分比和CD4/CD8比例均高于对照组,而CD8细胞百分比低于对照组(P均<0.05).实验组总有效率(48%)远远高于对照组(26%)(P<0.05).对照组患者出现血红蛋白下降、血小板减少、恶心呕吐、肾功能异常、心率异常、肢端麻木和脱发等不良反应发生率远远高于实验组(P均<0.05).结论 培美曲塞联合顺铂化疗治疗肺癌患者感染率低、有效率高、不良反应发生率低.

Clinical Observation of Pemetrexed Combined with Cisplatin for Lung Cancer

Objective To investigate the efficacy and side effects of pemetrexed combined with cisplatin for lung cancer . Methods 100 cases of patients with lung cancer ,according to clinical diagnosis and the patient 's situation,were divided into 2 groups,with 50 cases in each.The control group received changchun vinorelbine plus cisplatin ,the experimental group received pemetrexed combined with cisplatin .Infectious ratio ,treatment effect ,adverse reactions ,immune status and other conventional pa-rameters before and after treatment were recorded ,and data received statistical analysis .Results The T cell subpopulations were changed in both groups after treatment .And after treatment,the percentage of CD3,CD4 and CD4/CD8 ratio were higher in the experimental group than those of the control group (all P<0.05),while the percentage of CD8 cells was lower than that of the control group(P<0.05).The effective rate of the experimental group (48%) was higher than that of the control group (26%)(P<0.05).The incidence of hemoglobin,thrombocytopenia,nausea and vomiting,renal dysfunction,abnormal heart rate,limb numbness and hair loss in the control group were higher than those of the experimental group (all P<0.05).Conclusion Peme-trexed combined with cisplatin for lung cancer is safe with lower infectious ratio ,higher curative efficacy ,and lower adverse reac-tions.